These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 23395519)

  • 1. Successful treatment of severe delayed pressure angio-oedema with omalizumab.
    Rodríguez-Rodríguez M; Antolin-Amerigo D; Barbarroja-Escudero J; Sánchez-González MJ; Alvarez-Mon M
    Allergol Immunopathol (Madr); 2014; 42(1):78-80. PubMed ID: 23395519
    [No Abstract]   [Full Text] [Related]  

  • 2. Complete remission of severe chronic recurrent angioedema of unknown cause with omalizumab.
    von Websky A; Reich K; Steinkraus V; Breuer K
    J Dtsch Dermatol Ges; 2013 Jul; 11(7):677-8. PubMed ID: 23575040
    [No Abstract]   [Full Text] [Related]  

  • 3. Failure of omalizumab and successful control with ketotifen in a patient with vibratory angio-oedema.
    Pressler A; Grosber M; Halle M; Ring J; Brockow K
    Clin Exp Dermatol; 2013 Mar; 38(2):151-3. PubMed ID: 22731986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update and insights into treatment options for chronic spontaneous urticaria.
    Marrouche N; Grattan C
    Expert Rev Clin Immunol; 2014 Mar; 10(3):397-403. PubMed ID: 24527948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of a bullous urticaria with omalizumab.
    Ozturk AB; Kocaturk E; Ozturk E
    Allergol Int; 2014 Sep; 63(3):495-7. PubMed ID: 24957115
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
    Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
    J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab reduces corticosteroid use in patients with severe allergic asthma: real-life experience in Israel.
    Rottem M
    J Asthma; 2012 Feb; 49(1):78-82. PubMed ID: 22149205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab. An option in vernal keratoconjunctivitis?
    Sánchez J; Cardona R
    Allergol Immunopathol (Madr); 2012; 40(5):319-20. PubMed ID: 21975146
    [No Abstract]   [Full Text] [Related]  

  • 9. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy.
    Kopp MV; Hamelmann E; Bendiks M; Zielen S; Kamin W; Bergmann KC; Klein C; Wahn U;
    Pediatr Allergy Immunol; 2013 Aug; 24(5):427-33. PubMed ID: 23799935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey.
    Deschildre A; Marguet C; Salleron J; Pin I; Rittié JL; Derelle J; Taam RA; Fayon M; Brouard J; Dubus JC; Siret D; Weiss L; Pouessel G; Beghin L; Just J
    Eur Respir J; 2013 Nov; 42(5):1224-33. PubMed ID: 23520319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment of severe recalcitrant atopic dermatitis with omalizumab, an anti-immuno-globulin E.
    Quist SR; Ambach A; Göppner D; Quist J; Franke I; Bonnekoh B; Gollnick HP
    Acta Derm Venereol; 2013 Mar; 93(2):206-8. PubMed ID: 23042516
    [No Abstract]   [Full Text] [Related]  

  • 12. Omalizumab under 12 years old: real-life practice.
    Pite H; Gaspar Â; Paiva M; Leiria-Pinto P
    Allergol Immunopathol (Madr); 2013; 41(2):133-6. PubMed ID: 22560014
    [No Abstract]   [Full Text] [Related]  

  • 13. Monitoring omalizumab treatment efficacy in chronic urticaria by the basophil activation test.
    Rodríguez-Trabado A; Fernández Pereira LM; Romero-Chala S; García-Trujillo JA; Cámara Hijón C
    Allergol Immunopathol (Madr); 2012; 40(6):390-2. PubMed ID: 22178123
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatics.
    Pace E; Ferraro M; Bruno A; Chiappara G; Bousquet J; Gjomarkaj M
    J Asthma; 2011 May; 48(4):387-92. PubMed ID: 21391878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects.
    Busse W; Spector S; Rosén K; Wang Y; Alpan O
    J Allergy Clin Immunol; 2013 Aug; 132(2):485-6.e11. PubMed ID: 23591271
    [No Abstract]   [Full Text] [Related]  

  • 16. An algorithm for treating chronic urticaria with omalizumab: dose interval should be individualized.
    Uysal P; Eller E; Mortz CG; Bindslev-Jensen C
    J Allergy Clin Immunol; 2014 Mar; 133(3):914-5.e2. PubMed ID: 24360324
    [No Abstract]   [Full Text] [Related]  

  • 17. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.
    Özgür ES; Özge C; Ïlvan A; Naycı SA
    J Asthma; 2013 Aug; 50(6):687-94. PubMed ID: 23557459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful use of omalizumab in an inadequately controlled type 2 diabetic patient with severe insulin allergy.
    Cavelti-Weder C; Muggli B; Keller C; Babians-Brunner A; Biason-Lauber A; Donath MY; Schmid-Grendelmeier P
    Diabetes Care; 2012 Jun; 35(6):e41. PubMed ID: 22619293
    [No Abstract]   [Full Text] [Related]  

  • 19. Omalizumab (an anti-IgE antibody) in the treatment of severe atopic eczema.
    Ramírez del Pozo ME; Contreras Contreras E; López Tiro J; Gómez Vera J
    J Investig Allergol Clin Immunol; 2011; 21(5):416-7. PubMed ID: 21905512
    [No Abstract]   [Full Text] [Related]  

  • 20. Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticaria patients: a real life survey.
    Büyüköztürk S; Gelincik A; Demirtürk M; Kocaturk E; Colakoğlu B; Dal M
    J Dermatol; 2012 May; 39(5):439-42. PubMed ID: 22221177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.